NS 105

Known as: NS-105 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1997-1999
02419971999

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2000
2000
The involvement of metabotropic glutamate (mGlu) receptors in the modulatory actions of a novel cognition enhancer, (+)-5-oxo-D… (More)
Is this relevant?
1999
1999
The effects of (+)-5-oxo-D-prolinepiperidinamide monohydrate (NS-105) on the scopolamine-, electrolytic lesion of the nucleus… (More)
Is this relevant?
1999
1999
The absorption, metabolism and excretion of NS-105 ((+)-5-oxo-D-prolinepiperidinamide monohydrate, CAS 110958-19-5), a novel… (More)
Is this relevant?
1999
1999
Pharmacokinetics of NS-105, a novel agent for cerebrovascular disease, in elderly subjects were compared with those in younger… (More)
Is this relevant?
1999
1999
The tissue distribution and transfer into the fetus and milk of NS-105 ((+)-5-oxo-D-prolinepiperidinamide monohydrate, CAS 110958… (More)
Is this relevant?
1997
1997
The effect of (+)-5-oxo-D-prolinepiperidinamide monohydrate (NS-105), a novel cognition enhancer, on adenylate cyclase activity… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 6
Is this relevant?
1997
1997
The effect of a novel cognition enhancer [(+)-5-oxo-D-prolinepiperidinamide monohydrate] (NS-105) on cAMP formation was… (More)
Is this relevant?
1997
1997
We have previously found that a cognition enhancer [(+)-5-oxo-D-prolinepiperidinamide monohydrate] (NS-105) reversed the… (More)
Is this relevant?